Stock OHR PHARMACEUTICAL INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company OHR Pharmaceutical Inc Nasdaq

Equities

US67778H3093

Biotechnology & Medical Research

Business Summary

NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.

Managers

Managers TitleAgeSince
Todd Branning CEO
 Chief Executive Officer 54 22-01-09
Dani Stoltzfus PRN
 Corporate Officer/Principal - -
Ron Sarkar PRN
 Corporate Officer/Principal - 21-10-31
Alan Scrivner LAW
 General Counsel - 21-08-31
Shannon McCarthy HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Dov Goldstein CHM
 Chairman 56 19-07-11
Eric Richman BRD
 Director/Board Member 63 19-07-11
Franklyn Prendergast BRD
 Director/Board Member 79 19-07-11
Gerald McDougall BRD
 Director/Board Member 57 21-05-10

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,751,590 3,249,699 ( 86.62 %) 0 86.62 %

Shareholders

NameEquities%Valuation
Dietrich Stephan
6.386 %
238,162 6.386 % 107 173 $
Symetryx Corp.
5.161 %
192,481 5.161 % 86 616 $
Greenlight Capital, Inc.
3.656 %
136,350 3.656 % 61 358 $
Barry Shiff
2.936 %
109,508 2.936 % 49 279 $
Aleta Shiff
2.171 %
80,973 2.171 % 36 438 $
Kershner Trading Americas LLC
2.007 %
74,861 2.007 % 33 687 $
Point72 Asset Management LP
1.676 %
62,500 1.676 % 28 125 $
Renaissance Technologies LLC
1.528 %
56,967 1.528 % 25 635 $
UBS Securities LLC
1.389 %
51,792 1.389 % 23 306 $
Carnegie Mellon University
1.260 %
46,970 1.260 % 21 137 $

Company contact information

NeuBase Therapeutics, Inc.

350 Technology Drive Suite 421

15219, Pittsburgh

+

http://www.neubasetherapeutics.com
address OHR Pharmaceutical Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.81% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.47B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.33B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NBSE Stock
  4. Stock
  5. Company OHR Pharmaceutical Inc